Press Releases

The following UK & Ireland Press Releases contain information that is intended for journalists only.
For media enquiries about our press releases please contact mediaenquiries.UK-IE@ipsen.com.

CRSC-GB-000036

September 2022


9 results

NICE recommends Cabometyx® (cabozantinib) for previously tre...

Cabozantanib has been recommended by NICE as an option for treating advanced hepatocellular carcinoma (HCC),…

Tánaiste joins Ipsen Ireland to launch upgraded manufacturin...

Dublin, Ireland, 25th/26th September 2022 Tánaiste joins Ipsen Ireland to launch upgraded manufacturing site in…

Ipsen announced overall Pharma Industry Company of the Year ...

Ireland, May 2022 Blanchardstown-based, biopharmaceutical Ipsen has been announced overall Pharma Industry Company of the…

Ipsen appoints Guy Oliver as General Manager, UK & Irela...

SLOUGH, UK, 21 March 2022 — Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointment…

Secretary of State for Wales marks new investment in Ipsen’s...

WREXHAM, UK, 24 February 2022 Today, Simon Hart MP, Secretary of State for Wales, visited…

Advanced kidney cancer patients in Scotland become amongst t...

Advanced kidney cancer patients in Scotland become amongst the first in world to access CABOMETYX®▼…

Ipsen shares results from innovative research partnership ex...

In partnership with New Scientist, Ipsen UK has surveyed almost 800 young people to understand…

New campaign launches to break down taboos around prostate c...

 Prostate cancer is the most diagnosed cancer in the UK, with 57,192 men diagnosed in…

Ipsen and Mendelian Announce Landmark Partnership to Reshape...

Initially focusing on two rare conditions, MendelScan technology will integrate with patient records to aid…

© Ipsen Group 2022